Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Implementing the 3Rs in Swiss Preclinical Research: A Focus on Refinement in Dosing Techniques

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Implementing the 3Rs in Swiss Preclinical Research: A Focus on Refinement in Dosing Techniques

Implementing the 3Rs in Swiss Preclinical Research: Refinement in Dosing Techniques

CELL & GENE | RNA | BIOLOGICS

Executive Summary (TL;DR): In preclinical research, particularly for advanced cell and gene therapies, the principle of “Refinement” from the 3Rs is directly linked to data quality and translational success. By implementing advanced, minimally invasive dosing techniques, we reduce subject stress and biological variability, generating more precise and reproducible datasets. This approach strengthens IND-enabling packages and aligns with the highest ethical standards mandated by Swiss and global regulatory bodies.

What constitutes “refinement” in preclinical dosing?

Refinement involves modifying husbandry or experimental procedures to minimize pain, suffering, and distress. In dosing, this includes using smaller gauge needles, employing image-guidance for precise anatomical targeting, automating delivery for consistent infusion rates, and ensuring comprehensive acclimation and habituation of subjects to procedures.

How do refined dosing techniques impact study outcomes and data variability?

By minimizing procedural stress, refined techniques reduce the release of confounding stress hormones and physiological responses that can obscure the true effects of a test article. This leads to lower inter-animal variability, tighter data sets, and increased statistical power, often allowing for a reduction in group sizes.

What technologies does Franklin Biolabs use for precise dosing?

Our teams utilize a range of technologies tailored to the specific route of administration and therapeutic modality. This includes micro-infusion pumps for controlled delivery rates, ultrasound-guided injection systems for accurate targeting of specific tissues, and non-invasive administration methods where scientifically justified.

How does this approach align with Swiss and international animal welfare standards?

Our commitment to refinement directly supports compliance with standards set by AAALAC and the USDA. This philosophy is fully aligned with the stringent ethical and scientific expectations of the Swiss Federal Food Safety and Veterinary Office (FSVO) and other international regulatory authorities, ensuring that all studies are conducted to the highest possible welfare standards.

The Link Between Procedural Refinement and Data Integrity

In any GxP-compliant preclinical program, the integrity of the data is foundational. For complex modalities like AAV or lentiviral vectors, where biodistribution and expression levels are key endpoints, the method of administration can significantly influence outcomes. An imprecise or stressful dosing event can introduce variables that mask the true pharmacological or toxicological profile of a therapeutic candidate.

Our approach focuses on standardizing and refining every aspect of the in vivo process. This commitment to procedural excellence is a key factor in achieving a predictable 18-24 month IND timeline. By generating cleaner, more reliable data from the outset, we mitigate the risk of study repeats and ambiguous results that can delay program progression.

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

A Methodical Approach to In Vivo Dosing

The value of rigorous preclinical support was demonstrated by programs like the Gene Therapy Resource Program (GTRP), which successfully aided investigators in translating novel gene therapies toward clinical evaluation (PMID: 29130351). This success underscores that robust pharmacology and toxicology studies are pillars of translation. Refined dosing is a core component of this, ensuring that the biological activity of a novel vector is assessed with maximum accuracy. Operational Agility Accelerating In Vivo Success.

We employ a structured methodology to minimize variability:

  • Protocol Optimization: Each study protocol is reviewed to identify opportunities for refinement, from route of administration to post-procedure monitoring.

  • Subject Acclimation: Animals are carefully habituated to handling and procedural environments to reduce acute stress responses on the day of dosing.

  • Technology-Assisted Delivery: Where appropriate, we use instrumentation to ensure consistent volume, rate, and location of delivery across all subjects in a cohort.

This methodical execution within our >100,000 sq ft facility contributes directly to the quality of the data package. It is this focus on scientific and ethical rigor that has supported a 100% IND-enabling program success rate for our clients’ programs since 2019, with the Franklin Biolabs brand itself having launched in 2024.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities